(Alliance News) - Pfizer Inc on Tuesday said it will sell its entire residual stake in Haleon PLC, offloading approximately 662 million shares in the consumer health firm through a secondary offering and a share buyback agreement with Haleon. Read More
(Alliance News) - Stock prices in London were in the green at midday on Wednesday, amid news that the UK service sector only grew slightly in January while activity slowed in the eurozone. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The FTSE 100 closed higher on Thursday, while the pound fell, amid a welter of earnings and more pronouncements on tariffs by Donald Trump. Read More
(Alliance News) - Haleon PLC on Thursday saw organic sales growth accelerate in the fourth quarter but cautioned growth in 2025 would be weighted to the second-half. Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun out of GSK PLC in 2022 - Says Pfizer Inc representative Bryan Supran stepped down as a non-executive director on the Haleon board on Tuesday, following the reduction of Pfizer's stake in Haleon to less than 10%, and in line with the two firms' prior relationship agreement. Read More
(Alliance News) - Futura Medical PLC on Friday said it expects 2024 revenue and post-tax profit ahead of guidance, but warned of 2025 sales below market expectations, due to slow uptake in the US of its erectile dysfunction treatment. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
Futura Medical PLC - Guildford, Surrey-based sexual health products - Shares rise 4.5% on Wednesday as Futura reports positive results from a 'sensory' study of its WSD4000 treatment for sexual dysfunction in women. Futura explains that a sensory study assesses how healthy volunteers perceive product characteristics through their senses. The study involved 67 women with some degree of sexual dysfunction, and WSD4000 produced a positive change in a majority of them after four weeks. "Following the success of the study, alongside market research on the size of the opportunity following commercialisation, the board is recommending to proceed with an early feasibility study during H1 2025," Futura says. Read More
(Alliance News) - Pfizer Inc sold 700 million shares in Haleon PLC, as planned, more than halving its remaining stake, placing agent JPMorgan Securities PLC confirmed on Wednesday. Read More
(Alliance News) - Stocks in London are set to open higher on Wednesday, following consumer and producer price inflation data from the UK, ahead of CPI data from the US. Read More
(Alliance News) - Pfizer Inc is selling 700 million shares in Haleon PLC, more than halving its remaining stake, according to a statement from JPMorgan Securities on Tuesday. Read More
(Alliance News) - The FTSE 100 traded lower at midday on Friday although the pound stabilised ahead of key US jobs figures. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - Stock prices in London were mostly higher at midday on Monday, with investors mostly awaiting US inflation data in the afternoon. Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun-out of GSK PLC in 2022 - Says it has completed its acquisition of an additional 33% stake in Tianjin TSKF Pharmaceutical Co Ltd, its joint venture in China, bringing its total stake to 88%. The equity interest was acquired from its joint venture partners, Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd for a total of CNY4.47 billion, around GBP500 million. The transaction completed following approval by Da Ren Tang shareholders at the group's extraordinary meeting in November. Haleon now has the option to acquire Da Ren Tang's remaining 12% shareholding in TSKF. The joint venture accounted for around 40% of Haleon's China revenue in financial 2023. Read More